What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Another Take on the 2022 EULAR RA Treatment Guidelines
Dr. Peter Nash reviews the new 2022 EULAR RA Treatment Guidelines, presented at #EULAR2022.
Watch video →
EULAR 2022 - Day 2 Faculty Recap Panel
Dr. Jack Cush, Dr. Robert Chao and Dr. Richard Conway discuss interesting abstracts and seminars from day 2 at EULAR 2022.
Watch video →
2022 ASAS/EULAR Recommendations on the Management of Axial Spondyloarthritis
Dr. Peter Nash discusses the new ASAS/EULAR Spondyloarthritis treatment guidelines presented at EULAR 2022
Watch video →
RA Potpourri on Day One EULAR 2022: Not An Ugly Duckling
Dr. Jonathan Kay reports on RA-related sessions and abstracts from day 1 at EULAR 2022.
Watch video →
New 2022 ASAS/EULAR Recommendations on the Management of AxSpA
Dr. Sophia Ramiro (Leiden University Medical Center) presents an overview of the new Spondyloarthritis treatment guidelines from ASAS/EULAR Task Force.
Watch video →
EULAR 2022 - Day 1 Faculty Recap Panel
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at EULAR 2022 - Guidelines, Lupus, and more.
Watch video →
Dr. John Cush RheumNow
3 years 1 month ago
Provacative read from @VPrasadMDMPH on why we no longer need to or should wear masks in our clinics and hospitals (Yes, with COVID+ pts --- No, everywhere else). My advice: wear masks in high risk environments/situations. https://t.co/cECeieQ2YL https://t.co/PbX8xnfgqM
Dr. John Cush RheumNow
3 years 1 month ago
The 2022 ACR abstracts are published and posted for you. Let the Learning begin! https://t.co/ZqMAc8jV3U https://t.co/3iCGnzsPI5
Catherine Sims, MD DrCassySims
3 years 1 month ago
A summary slide from #grandrounds this morning on a talk about trying to differentiate #lupus #nephritis from #preeclampsia #RheumTwitter #MedTwitter https://t.co/R2rhhgQYIm
Dr. John Cush RheumNow
3 years 1 month ago
Mayo study of 3817 temporal artery biopsies performed on 2539 pts (1994-2004) - 681 (27%) +Bx on one side. Biopsy length HAD NO significant effect BX positivity. If 1-side initially Bx-, then Bx of the contralateral side yielded an added 7% Bx positivity https://t.co/Lr8hYHIlG7 https://t.co/alIpklPtsw
Two large RA registries have shown that pregnancy outcomes in rheumatoid arthritis (RA) patients is more related to RA disease activity rather than treatments use to control RA.
Incidence of acute coronary syndrome (ACS) was significantly higher among gout patients than in the general Swedish population, researchers found, even when data were adjusted for common comorbidities.
Dr. John Cush RheumNow
3 years 1 month ago
Taiwan population study shows increased all-cause mortality for psoriasis patients (HR 1.16; 1.13-1.19) vs. general population. https://t.co/p09mXTfXPw https://t.co/UVK3GMMmip
Dr. John Cush RheumNow
3 years 1 month ago
Study of 247 consecutive PsA pts shows that two-thirds (63.15%) had poor sleep quality. Poorer sleep was assoc w/ being female, higher joint counts, greater peripheral and axial disease activity, but fatigue & anxiety most explained poor sleep quality https://t.co/RTZqxtyIu9 https://t.co/OVtTQkFirD
Dr. John Cush RheumNow
3 years 1 month ago
Secukinumab retention in PsA: Study of 170 pts, 13% B27+, most w/ peripheral arthritis &70% on 150 mg/mo. Median retention 636 days. Peripheral arthritis was a predictor of better retention (HR 0.424). https://t.co/aZD9qD0jxm https://t.co/FlqRlcAZd1
Dr. John Cush RheumNow
3 years 1 month ago
The Atlantic has published an insightful article on "Brain Fog", especially as a Long Covid consequence (IMHO: Brain fogs primary cause is poor sleep, fibromyalgia, chronic fatigue - but can be complication to primary CNS events) https://t.co/SlwzRDSVSf https://t.co/qrBvV5oyUA
Dr. John Cush RheumNow
3 years 1 month ago
Doctor Appointment Wait Times are Up
Forbes reports that a recent Merritt Hawkins survey shows that patients are waiting an average of 26 days for a scheduled appointment with a doctor.
https://t.co/oJkLRzRR1y https://t.co/8zy0LgC7dt
Dr. John Cush RheumNow
3 years 1 month ago
TYK2 Inhibitor FDA Approved for Psoriasis
BMS made a mega bet on deucravacitinib, an in-house experimental TYK2 drug, in the leadup to the big Celgene buyout, keeping it while auctioning off Celgene’s top-selling Otezla to Amgen for $13.4 billion
https://t.co/wPN62jBIvL https://t.co/Cj6svOoiaJ
A Omar ahomar
3 years 1 month ago
I created an online version of the Modified Rodnan Skin Score (mRSS) to make it easier to calculate
References mentioned below tool:
https://t.co/5Us3usCTsC
@SindhuJohnson5 @Janetbirdope
#scleroderma #rheum #rheumatology
Charlie Clements ClementsCharl96
3 years 1 month ago
Nice table from the Poddubny et al., (2021) study which looks at some of the different characteristics between Axial SpA vs Axial PsA.
Axial PsA tends to have;
- Less frequent IBP
- Less HLAB27 +‘ve
- More frequent C-spine involvement https://t.co/XXQKBSfSQq
Leonard Calabrese LCalabreseDO
3 years 1 month ago
In your RHEUMATOLOGY practice how often are you seeing #LongCovid (new fatigue,brainfog,breathless etc) in your immune dis pts with COVID ( i.e. > 1 month) @CCalabreseDO @jeffsparks @zach_wallace_md @philipcrobinson @JYazdanyMD @alhkim @RheumNow @EBRheum @rheum_cat @AWIRGROUP
Poster Hall